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Summary Study objectives: To evaluate how serum lidocaine concentrations (SLC)
rise when lidocaine is administered by a Bronchofiberscopic Catheter Spray Device
(BCSD), and to demonstrate the effect on the aspiration speed of a substitute for
sputum when a catheter spray remains in the channel of the bronchofiberscope (BF).
Methods: This is a prospective randomized clinical study. After lidocaine ultrasonic
nebulizer, the BF was inserted orally. During the procedure patients received 4%
lidocaine by two methods. In Group 1, 11 patients received lidocaine by
bronchofiberscopic (BF) injection. In Group 2, 15 patients received lidocaine by
spraying from the+1:06mm catheter through the BF channel. SLC were measured
at 40min from onset of nebulization. Separately, we examined how effectively
sputum was aspirated through the BF channel with a catheter.
Results: Total lidocaine dose (TLD) is the total dose used for nebulization and for
the BF injection or spray. The TLD for Groups 1 and 2 were 698.27162.1mg
(mean7SD) and 498.77103.8mg, respectively (P ¼ 0:03). The SLC for Groups 1 and 2
were 1.2870.72 and 1.4870.70mg/l, respectively (P ¼ 0:49).
Conclusions: Using BCSD allows easier in administration of lidocaine and is not
associated with a significant increase in SLC in comparison with BF injection.
Although sputum aspiration using the BF inserted with our catheter was somewhat
slow, we did not feel inconvenient so much. Compared to the conventional method,
using BCSD may be preferable for patients and bronchoscopists.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
In many institutions, bronchofiberscopic (BF) ex-
amination is now performed under local anesthesia.
During BF examination, lidocaine is additionally
administered into the trachea and bronchus by
injection through the bronchofiberscope (BF) chan-
nel with a syringe.1,2 In this paper, we refer to this
type of administration of lidocaine as ‘‘BF injec-
tion’’. The BF injection itself induces coughing and
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is associated with uneven anesthesia in the trachea
and bronchus,3 and it is troublesome to do on a
repeated basis. Thus, we developed a system
allowing lidocaine to be easily sprayed repeatedly
in the bronchus.3 In this paper we introduced a
novel Bronchofiberscopic Catheter Spray Device
(BCSD) to alleviate patient discomfort. We demon-
strated the utility and safety of the BCSD in clinical
application.
Materials and methods
Instruments
Figure 1 shows the BCSD and its schematic drawing.
The BCSD consists of a gas–liquid mixing barrel,
stopcock with lever, and an attached catheter. The
barrel is a 5ml disposable syringe containing
lidocaine. The mouth of the barrel is closed by a
cap that has an inductive tube for oxygen gas.
Inside the barrel, there is a thin tube with a pinhole
to take in lidocaine, and this thin tube goes out to
the tip of the barrel. A 1m teflon catheter tube
(+1:06; 0.56mm inside diameter) is connected to
the barrel. The pressure of oxygen gas was adjusted
to 4 atm in clinical practice; the device withstands
up to 8 atm. Simple operation of a stopcock lever
allows ease in dosing of the lidocaine.
The spray device ejects 4% lidocaine at a
maximal rate of 0.05ml/s at 4 atm (Fig. 2).
Patients
This examination is a prospective randomized
clinical study. Twenty-six patients (male; 20,
female; 6) requiring diagnostic bronchofiberscopy
for biopsy, treatment, observation, etc., gave
consent to participation in this study. All patients
were medically stable without cardiac, kidney or
liver disease.
The total lidocaine dose (TLD) is the sum of the
lidocaine used in the nebulization and lidocaine
either injected or sprayed into the trachea and
bronchus. Venous blood samples were taken for
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Figure 1 (a) BCSD; (b) Schematic: (a) oxygen inlet, (b)
on-off stopcock with lever, (c) one-way bulb, (d) syringe
barrel, (e) tubing pinhole, and (f) catheter spray tip with
pinhole.
Figure 2 (a) Spraying through the catheter inserted
through the forceps channel. (b) Spraying lidocaine into
the bronchus does not obscure vision.
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measurement of serum lidocaine concentrations
(SLC) by fluorescence polarization immunoassay at
40min after the beginning of nebulization. Further
Loukides et al.4 reported that the peak plasma
concentration of lidocaine occurs within 20–30min
after the beginning of local anesthesia based on
measurements at frequent intervals (before, 5, 10,
20, 30, 45, 60, 90, 120min after initiation of
anesthesia). We decided to measure SLC 40min
after administration, as this time point that of the
expected was near peak concentration (20–30min).
All patients, after premedication (atropine sulfate
0.5mg, i.m.), received ultrasonic nebulization of
4ml of 4% lidocaine. Just prior to insertion of the
BF, 2ml of 4% lidocaine was sprayed additionally to
the pharyngo-larynx with a Jackson’s type atomi-
zer. Patients were randomly divided into 2 groups;
Group 1 included patients undergoing bronchofiber-
scopy by BF injection, and Group 2 included
patients undergoing bronchofiberscopy by the new
method using BCSD. Group 1 comprised 11 patients:
8 males, 3 females, aged 48–82 years old
(67.1716.8, mean7SD). Group 2 comprised 15
patients: 12 males, 3 females, aged 25–78 years
old (62.7711.4). The BF with a 2.00mm channel
for forceps or suction (Olympus BF type 240, Japan)
was inserted orally. In Group 1, we injected 1ml of
4% lidocaine solution at the vocal cord, trachea,
carina, right upper bronchus, right basal bronchus,
left main bronchus, left upper bronchus and left
lower bronchus. For patients coughing, we add
lidocaine after each cough. In Group 2, we sprayed
4% lidocaine solution on the vocal cord, trachea,
right main bronchus and left main bronchus using
the spray catheter of+1:06mm. Because we can
achieve satisfactory local anesthesia administra-
tion, we rarely need to lidocaine for observation
only.
Sputum aspiration performance study
During the BF examination it is necessary to
aspirate sputum whenever needed. When the
BF is loaded for BCSD, sputum must be aspirated
through the opening between the channel
and the inserted spray catheter. Therefore
we studied the aspiration ability of a viscous
starch test material (STM) as a substitute for
sputum.
The STM had coefficient of viscosity higher than
that of sputum. It was prepared from 4 g of starch
and 150ml of water. Starch and water were mixed,
heated until semi-transparent, and cooled to 221C.
We used an Olympus BF type 240 with a 2.00mm
channel and three different catheter sizes of spray
catheter: +1:06; 1:25 and 1:90mm (commercial
spray catheter: PW-6C-1, Olympus Optical Co.,
Ltd., Japan). Each catheter tube protruding 1mm
from the BF tip was tested under same conditions.
The aspiration pressure was 500mmHg, and the
time required to aspirate 25ml of STM was
measured.
Student’s unpaired t-test and Pearson’s correla-
tion coefficient was used for statistical analysis.
Results were considered statistically significant at
Po0:05:
Results
Clinical study
Table 1 shows TLD and SLC for patients of Group 1
and Group 2. The TLD of Group 1 ranged from 460
to 1000mg with a mean of 698.27162.1mg. The
TLD of Group 2 ranged from 340 to 680mg with a
mean of 498.77103.8mg. The TLD of Group 2 was
significantly less than that of Group 1 (P ¼ 0:03).
The SLC of Group 1 ranged from 0.5 to 2.7mg/l
with a mean of 1.2870.72mg/l. The SLC of Group 2
ranged from 0.6 to 2.7mg/l with a mean of
1.4870.70mg/l. There was no significant differ-
ence in SLC between the two groups (P ¼ 0:49).
Figure 3 demonstrates the relationship of TLD to
SLC. In Group 2, TLD was highly correlated with SLC
(correlation coefficient: r ¼ 0:81; Po0:01). How-
ever, in Group 1, there was no correlation between
TLD and SLC (correlation coefficient: r ¼ 0:59;
P40:05). No overdosage reactions of lidocaine
were observed in either group.
Total examination times from the nebulization in
Group 1 and Group 2 were 30–60min (40.578.8)
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Table 1 TLD and SLC of Group 1 and Group 2.
Mean TLD (mg) Mean SLC (mg/l)
Group 1 (n ¼ 11) 698.27162.1 (460–1000) 1.2870.72 (0.5–2.7)
Group 2 (n ¼ 15) 498.77103.8 (340–680) 1.4870.70 (0.6–2.7)
Values given as mean7SD.
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and 30–60min (40.379.2), respectively. There was
no significant difference between the two groups.
Sputum aspiration performance study
Table 2 shows the results of the aspiration studies.
The time required to aspirate 100ml of water using
the BF without a catheter was 10 s. The times to
aspirate using the BF loaded with+1:06; 1:25 and
1:90mm catheters were 22, 27 and 220 s, respec-
tively. When Olympus’s catheter (+1:90mm) was
loaded, aspiration took a very long time compared
with our catheter (+1:06mm). The time for
aspiration of 2ml of STM using the BF without a
catheter was 1.2 s. The time for aspiration using BF
with catheters of+1:06 or 1:25mm were 3.6 and
6.0 s, respectively. However, in the extremely
narrow slit of the channel with +1:90mm (PW-
6C-1) it took more than 50 s. The BF loaded with
Olympus’s catheter cannot aspirate sputum at bed
side.
Discussion
Even after lidocaine nebulization, the traditional
BF injection produces coughing and discomfort, and
its anesthetic effect is uneven.1,2 It is also trouble-
some to perform the bronchofiberscopy. On the
other hand, patients experienced no discomfort
when spraying lidocaine.
In the past such spray catheter devices have not
allowed effective aspiration of sputum. The spray
device (Olympus PW-6C-1) has an external catheter
diameter of 1.9mm, which is too large for effective
aspiration through the slit between the channel and
the catheter. Using a PW-6C-1 for additional local
anesthesia, we would have to remove the catheter
from the channel at every aspiration.
We previously reported a method in which a
Jackson’s atomizer was used as a gas–liquid mixer.3
Although there are other reports5–8 of topical
anesthesia of the nasal cavity, pharynx and larynx
by sprays, there has been few reported uses of a
catheter inserted in the channel. Our BCSD is
constructed from a syringe barrel equipped with a
pin-holed tube, a thin long catheter and an oxygen
gas inductive tube. In addition, while anesthetizing
by our device, the patient’s SaO2 did not deterio-
rate (data not shown). The patients did not cough,
and were not discomforted by anesthetizing at any
time. We do not have to pull out our catheter
during observation because there is sufficient
aspiration of sputa through the channel. After
observation, we sprayed lidocaine one time using
our device, pull out the device, then insert the
biopsy or needle aspiration tool. It is very rare for
us to re-insert our anesthetic catheter during
biopsy or aspiration biopsy. The BCSD is simple
and easy for operation and allows the aspiration of
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Figure 3 Relationship between TLD and SLC in Groups
1(a) and 2(b).
Table 2 The time to absorb samples of water and the STM.
No device catheter Inserted device catheter
Catheter diameter (mm) None +1:06 +1:25 +1:90
Time to aspirate water 100ml (s) 10 22 27 220
Time to aspirate STM 2ml (s) 1.2 3.6 6.0 450
+: catheter dimension outside diameter.
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sputum while keeping the spray catheter in the BF
channel.
Lidocaine administration by ultrasonic nebuliza-
tion has been reported to be safe.9,10 In contrast,
there is a report that ultrasonic nebulization of
lidocaine is similar to intravenous administration in
pharmacokinetics.11 We thus evaluated how SLC
rises when administered by BF injection or by
catheter spray. In our study the TLD of the
spray group (498.77103.8mg) was significantly
less than that of the injection group
(698.27162.1mg). However, the SLCs of both
groups were almost the same: 1.4870.70mg/l
(spray group) versus 1.2870.72mg/l (injection
group). The average of SLC for both groups was
considerably lower than the level (5mg/l)
at which side effects of lidocaine are reported to
appear.12 Clinically, no adverse reactions were
observed. TLD was highly correlated to SLC in the
spray group (r ¼ 0:81), but the relationship be-
tween them was indistinct in the injection group
(r ¼ 0:59). In BF injection we must immediately
aspirate the excess of lidocaine after injection, and
its range of local anesthesia is narrow. On the other
hand, our BCSD can put a wide area under local
anesthesia with only a small amount of lidocaine
due to the good absorption rate. The higher
correlation coefficient suggests a more predictable
dose-response curve and thus dosing parameters for
safety can be more easily predicted with the spray
technique.
During bronchofiberscopy it is necessary to
aspirate sputum. Our experiment demonstrated
that the aspiration speed of a starch preparation
depends on the spray catheter diameter. The time
for aspiration of 2ml of STM using BF with our
device was 3.6 s, while that with the Olympus PW-
6C-1 spray system was more than 50 s. Clinically,
sputum cannot be aspirated with a PW-6C-1
inserted in the channel. In contrast, we can easily
aspirate sputum samples when using our spray
catheter of size+1:06mm.
Our BCSD and Olympus’s PW-6C-1 cost less than
3000 Japanese yen and 18,000 Japanese yen,
respectively. Our current BCSD model has a simple
structure and is almost handmade. We can expect
greater reduction in cost if we mass-produce the
device.
In conclusion, using BCSD we can perform BF
without coughing and discomfort. We can easily
aspirate the sputum while using BCSD, and we can
adequately predict SLC from TLD and reduce the
risk of side effects because TLD is highly correlated
to SLC in this spray technique. We can achieve
effective SLC in safe and wide ranging anesthesia
without aspirating excess lidocaine. Thus, we
believe that this simple and inexpensive device is
useful for administration of lidocaine during
bronchofiberscopy. The spray technique using our
device is easily performed by the physician and well
tolerated by the patient.
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